Previous studies have shown that roxadustat, also known as FG‐4592, is a first‐in‐class small molecule oral PHD inhibitor, which is currently used for the treatment of anaemia in patients with chronic kidney disease(CKD) in phase III clinical trials.20 So we evaluated the effects of FG‐4592 in radioprotection, which may facilitate its use as a protector after large‐scale accidental radiation incidents or as part of radiotherapy treatment in the future.17 Here, PDC is linked to anemia (phenotype).